UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 567
- Registration Number
- NCT00160641
- Locations
- 🇺🇸
172, Palm Desert, California, United States
🇺🇸170, Santa Maria, California, United States
🇺🇸194, Whittier, California, United States
A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 590
- Registration Number
- NCT00160602
Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 100
- Registration Number
- NCT00160628
A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 170
- Registration Number
- NCT00160511
Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 251
- Registration Number
- NCT00160654
- Locations
- 🇸🇬
N01036 806, Singapore, Singapore
🇨🇳N01036 818, Tainan, Taiwan
🇲🇾N01036 813, Kuala Lumpur, Malaysia
Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 207
- Registration Number
- NCT00160563
Testing the Efficacy of Different Dosages of Lercanidipine to Reduce Hypertensive Blood Pressure in Normal Weight and Obese Patients
Not Applicable
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-03-10
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 180
- Registration Number
- NCT00160498
A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 152
- Registration Number
- NCT00160667
A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 596
- Registration Number
- NCT00160524
- Locations
- 🇨🇿
18009, Melnik, Czechia
🇵🇱33009, Warszawa, Poland
🇷🇸35005, Belgrade, Serbia
Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 402
- Registration Number
- NCT00160693
© Copyright 2024. All Rights Reserved by MedPath